Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer

The clinical use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors has significantly improved the prognosis of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (ABC/mBC), which almost achieved the doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yanmei, Zhang, Yu, Pi, Hao, Sheng, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237121/
https://www.ncbi.nlm.nih.gov/pubmed/32523378
http://dx.doi.org/10.2147/CMAR.S250632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237121/
https://www.ncbi.nlm.nih.gov/pubmed/32523378
http://dx.doi.org/10.2147/CMAR.S250632

Ejemplares similares